CClinicalTrials.gg
Status unknownNCT04536428Updated Sep 2, 2020

ClearEndoclip Versus EZ Clip for Upper Gastrointestinal Ulcer Bleeding

An interventional study of Endoscopic hemostasis with clip in Peptic Ulcer Hemorrhage, sponsored by Ajou University School of Medicine. Status unknown at 1 site in Korea, Republic of. Open to participants aged 20 Years to 80 Years. Per ClinicalTrials.gov, last updated 2020-09-02.

Sponsored by Ajou University School of Medicine · Not applicable, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Aug 2020), so the status shown — last known as Active, not recruiting — may be out of date.
Phase
Not applicable
Study type
Interventional
Enrollment
176
Allocation
Randomized
Ages
20 Years to 80 Years
Sex
All
01

Study summary

We are going to conduct a comparative study to analyze the clinical effectiveness and user convenience of EZ clips that have been used in upper gastrointestinal ulcer bleeding and newly developed clip (ClearEndoclip, FineMedix, Taegu) in Korea.

  1. Research hypothesis and purpose
  • This study was designed to prove the hypothesis that the hemostatic effect of newly developed endoscopic clip (ClearEndoclip, FineMedix, Taegu, Korea) is not inferior to that of EZ clip (Olympus, Tokyo, Japan) in the treatment of hemostasis for patients who visited the upper gastrointestinal ulcer bleeding.
  • This study was designed as a multi-center (9 institutions), open-labelled, randomized comparative clinical trial (1:1 ratio).
Read the detailed description
  1. Design of this study

    1. Stratified randomization is performed, and the variable used for stratification is the patient's age (65 years or older, 65 years or less).
    2. The existing clip (control) and the domestic clip (experimental group) are divided by the block size randomization method of size 4 for each floor.
  2. Patients and Methods

    1. inclusion criteria

      • Men and women aged 20 to 80
      • The patients who came to the emergency room due to upper gastrointestinal bleeding with as follows: peptic ulcer with acute bleeding or protruding vascular exposure (Forrest class Ia-IIa), anastomotic vascular ulcer bleeding, bleeding from endoscopic submucosal dissection or endoscopic mucosal resection site after 24 hours
      • American Society of Anesthesiologist (ASA) Physical Status 1 - 3
      • Patients with adequate patient compliance and adequate geographical distance for follow-up. character
    2. exclusion criteria

      • Patients with gastrointestinal bleeding who are not recommended to clip Bleeding from a malignant tumor Hemorrhagic gastritis Angiodysplasia variceal bleeding
      • Bleeding during endoscopic submucosal dissection or endoscopic mucosal resection
      • Patients with insufficient clinical information
      • Pregnant or lactating patients
      • Patients or guardians who have not obtained informed consent
    3. The number of patients

      • The number of subjects was calculated based on a non-inferiority study

        • The reported rate of rebleeding after hemostasis using the conventional hemoclip: about 5%.
        • 2.5% one-sided test, 80% power, and non-inferiority limit set to 10%

          • 75 subjects are required for each group, and 83 subjects are required if the drop rate is assumed to be 10%.
    4. Methods

      • After completing an informed consent form to the subjects who wish to participate in the study at the time of visit, basic clinical variables are checked.
      • First endoscopic hemostasis is performed. In this time, EZ clip is used for the subjects assigned to the control group, and ClearEndoclip is used for the subjects assigned to the experimental group to target blood vessels in the ulcer. At the same time, clinical parameters related to hemostasis are recorded.
      • After hemostasis is performed, rebleeding and complications are tracked up to 30 days after the procedure.
    5. Variables to be collected

      • At the time of visit: age, gender, height, weight, drug use (anticoagulant/antiplatelet agents, NSAIDs, steroids), underlying diseases (cirrhosis, diabetes, end-stage renal failure, heart disease, lung disease), hematological data, hemoglobin, Complete Rockall score
      • At the time of primary endoscopic hemostasis: location of ulcer, size of ulcer, size of exposed blood vessel (based on 2mm), forrest classification, total number of clips used, number of failed clips, usage and usage of epinephrine, procedure time (minutes) , Clip hemostasis success, treatment after clip hemostasis failure
      • After hemostasis: rebleeding (within 7 days), number of clips and bleeding from the follow-up endoscope after 48 hours, death within 30 days, ICU hospitalization date, total hospitalization date, complications of hemostasis, Helicobacter pylori
02

Conditions studied

  • Peptic Ulcer Hemorrhage

Keywords

  • peptic ulcer
  • hemorrhage
  • stomach
  • duodenum
03

In context

Peptic Ulcer

193 studies on the registry are indexed under Peptic Ulcer; 31 are open to participants now.

This study's planned enrollment of 176 is above the median of 150 across 142 interventional studies indexed under Peptic Ulcer.

Browse Peptic Ulcer studies →

Lead sponsor

Ajou University School of Medicine is the lead sponsor of 171 studies on the registry; 16 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Men and women aged 20 to 80
  • The patients who came to the emergency room due to upper gastrointestinal bleeding with as follows: peptic ulcer with acute bleeding or protruding vascular exposure (Forrest class Ia-IIa), anastomotic vascular ulcer bleeding, bleeding from endoscopic submucosal dissection or endoscopic mucosal resection site after 24 hours
  • American Society of Anesthesiologist (ASA) Physical Status 1 - 3
  • Patients with adequate patient compliance and adequate geographical distance for follow-up. character

Exclusion criteria

Exclusion Criteria:

  • Patients with gastrointestinal bleeding who are not recommended to clip Bleeding from a malignant tumor Hemorrhagic gastritis Angiodysplasia variceal bleeding
  • Bleeding during endoscopic submucosal dissection or endoscopic mucosal resection
  • Patients with insufficient clinical information
  • Pregnant or lactating patients
  • Patients or guardians who have not obtained informed consent
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
176 participants (estimated)

Study arms

  • Experimental
    ClearEndoclip

    This arm is a group in whom ClearEndoclip would be used for the treatment of bleeding.

    Device: Endoscopic hemostasis with clip

  • Active comparator
    EZ clip

    This arm is a group in whom EZ clip would be used for the treatment of bleeding.

    Device: Endoscopic hemostasis with clip

Interventions

  • DeviceEndoscopic hemostasis with clip

    This intervention is performed as the following orders. * The tip of endoscope is accessed to a bleeding site. * The accurate visualization of bleeding site is done. * A sheath of delivery system of clip is inserted through a working channel of endoscope. * The end of clip is opened in front of the bleeding site. If needed, clip could be rotated to adjust to a bleeding target. * The both ends of clip are placed on both sides of a bleeding site. * If bleeding is still continued, additional placements of clip are tried until bleeding stops.

06

What researchers measure

Primary outcomes

  1. Rebleeding rate after endoscopic hemostasis

    The rate of rebleeding at the site of bleeding within 7 days after the first endoscopic hemostasis, which should be identified endoscopically.

    Time frame: upto 7 days

Secondary outcomes

  1. Satisfaction scores of the operator and the assistant

    the degree in ten-scale in terms of an endoscopic visibility to a bleeding site and the easiness of use. the minimum: 1(worst value), the maximum: 10(best)

    Time frame: during endoscopic procedure

  2. Failure rate of clip installation

    Ratio of unsuccessful clips to total number of clips used

    Time frame: during endoscopic procedure

07

Study locations

1 site
  • Sun Gyo Lim
    Suwon, Gyeonggi 16499, Korea, Republic of
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Sep 2, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04536428
Lead sponsor
Ajou University School of Medicine
Collaborators
Keimyung University Dongsan Medical Center, Korea University Anam Hospital, National Cancer Center, Korea, Nowon Eulji Medical Center, Pusan National University Hospital, Wonju Severance Christian Hospital, Inha University Hospital, Presbyterian medical center
Responsible party
Sun Gyo Lim, MD (Associate professor, Ajou University School of Medicine) — Principal investigator
First posted
Sep 2, 2020
Start date
Aug 24, 2020
Primary completion
Jul 31, 2021 (estimated)
Completion
Dec 1, 2021 (estimated)
Last update
Sep 2, 2020

Study contacts

Sun Gyo Lim
principal investigator · Department of Gastroenterology, Ajou University School of Medicine

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Aug 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion